Steven H. Stein
Known title: EVP & Chief Medical OfficerCIK: 0001673776
Associated companies
Transaction History
| INCY | ▼ Sell | Open Market | 1,877 | $215K | 7/16/2026 | View on chart |
| INCY | ▲ Buy | Grant | 9,798 | $0 | 7/16/2026 | View on chart |
| INCY | ▼ Sell | Open Market | 28,237 | $3.2M | 7/15/2026 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 3,088 | $355K | 7/15/2026 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 21,830 | $2.5M | 7/14/2026 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 2,177 | $254K | 7/2/2026 | View on chart |
| INCY | ▲ Buy | Grant | 39,049 | $0 | 4/15/2026 | View on chart |
| INCY | ▼ Sell | Open Market | 15,634 | $1.6M | 1/5/2026 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 13,292 | $1.3M | 12/31/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 20,105 | $2.1M | 12/2/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 17,093 | $1.7M | 12/1/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 2,559 | $263K | 12/1/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 2,995 | $287K | 11/5/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 1,044 | $100K | 11/5/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 5,233 | $535K | 11/5/2025 | View on chart |
| INCY | ▲ Buy | Option Exercise | 1,194 | $100K | 11/5/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 3,706 | $252K | 7/21/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 1,596 | $109K | 7/15/2025 | View on chart |
| INCY | ▲ Buy | Grant | 12,277 | $0 | 7/15/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 14,952 | $1.0M | 7/14/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 1,555 | $109K | 7/14/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 12,714 | $867K | 7/2/2025 | View on chart |
| INCY | ▲ Buy | Grant | 37,198 | $0 | 4/1/2025 | View on chart |
| INCY | ▲ Buy | Grant | 20,967 | $0 | 4/1/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 12,352 | $898K | 1/21/2025 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 10,692 | $775K | 1/15/2025 | View on chart |
| INCY | ▼ Sell | Open Market | 11,608 | $704K | 8/12/2024 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 1,555 | $100K | 7/15/2024 | View on chart |
| INCY | ▲ Buy | Grant | 13,895 | $0 | 7/15/2024 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 8,316 | $491K | 7/2/2024 | View on chart |
| INCY | ▲ Buy | Grant | 7,377 | $0 | 2/14/2024 | View on chart |
| INCY | ▼ Sell | Open Market | 7,365 | $482K | 1/3/2024 | View on chart |
| INCY | ▼ Sell | Open Market | 21,511 | $1.4M | 8/1/2023 | View on chart |
| INCY | ▲ Buy | Grant | 13,535 | $0 | 7/14/2023 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 8,442 | $524K | 7/3/2023 | View on chart |
| INCY | ▲ Buy | Grant | 4,980 | $0 | 1/20/2023 | View on chart |
| INCY | ▼ Sell | Open Market | 28,399 | $2.3M | 1/4/2023 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 3,856 | $306K | 7/5/2022 | View on chart |
| INCY | ▲ Buy | Grant | 18,941 | $0 | 7/2/2022 | View on chart |
| INCY | ▼ Sell | Tax Withholding | 11,488 | $869K | 6/28/2022 | View on chart |
| INCY | ▲ Buy | Grant | 28,926 | $0 | 1/1/2022 | View on chart |
| INCY | ▲ Buy | Grant | 379 | $0 | 11/19/2021 | View on chart |
| INCY | ▲ Buy | Grant | 2,355 | $0 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes
Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.